Tickers

1. Composite Trajectory Verdict

For a pre-revenue clinical-stage biotechnology company, the cash flow statement and balance sheet (particularly cash runway and operating cash burn) carry the most weight, as they directly measure the ability to fund ongoing development until potential product approval; the income statement is secondary but reflects the trend in operating burn rate.

Composite Trajectory: Improving

The annual comparison (FY2025 vs. FY2024) shows a 26% reduction in net loss ($190.9M vs. $257.6M) and a 23% reduction in total operating expenses ($209.3M vs. $273.2M) (10-K 2025-12-31, Consolidated Statements of Operations). The six-month comparison (H1 2026 vs. H1 2025) shows a 23% reduction in net loss ($85.3M vs. $110.7M) and a 20% reduction in total operating expenses ($97.7M vs. $122.0M) (10-Q 2026-06-30, MD&A Results of Operations). Operating cash burn improved 25% annually ($149.2M vs. $200.3M) and 51% for the six-month period ($44.9M vs. $92.0M) (10-K 2025-12-31, Consolidated Statements of Cash Flows; 10-Q 2026-06-30, Cash Flows). Cash, cash equivalents and investments rose to $423.6M at June 30, 2026 from $258.3M at December 31, 2025, extending the projected cash runway into Q1 2029 (10-Q 2026-06-30, MD&A Liquidity and Capital Resources). The only countervailing signal is a 19% increase in G&A in H1 2026 driven by one-time leadership transition costs, but this is explicitly noted as non-recurring (10-Q 2026-06-30, MD&A General and Administrative Expenses).

2. Red Flags

• Revenue remains negligible and non-recurring: FY2025 revenue was $0; FY2024 revenue was $22K; H1 2026 revenue of $4.6M stems entirely from termination of the Overland license agreement, not product sales (10-K 2025-12-31, Consolidated Statements of Operations; 10-Q 2026-06-30, MD&A Revenues).
• Accumulated deficit continues to grow: Accumulated deficit increased to $2.096B at June 30, 2026 from $2.011B at December 31, 2025 and $1.820B at December 31, 2024 (10-K 2025-12-31, Consolidated Balance Sheets; 10-Q 2026-06-30, Consolidated Balance Sheets).
• Dependence on equity financing for cash runway: The $187.9M April 2026 public offering provided the bulk of the $209.0M financing cash inflow in H1 2026; without it, cash would have declined (10-Q 2026-06-30, Cash Flows; MD&A Liquidity and Capital Resources).
• Recurring impairment charges on subleased facilities: Long-lived asset impairments of $2.4M in FY2025 and $15.7M in FY2024 were recorded for subleased South San Francisco buildings, with an additional $1.0M in Q2 2025 (10-K 2025-12-31, Note 5; 10-Q 2026-06-30, MD&A Impairment of Long-Lived Asset).
• Stock-based compensation remains a large non-cash expense: $37.6M in FY2025 and $20.7M in H1 2026, though down from $51.7M in FY2024 and $20.9M in H1 2025 (10-K 2025-12-31, Note 9; 10-Q 2026-06-30, Cash Flows).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Improving

Net loss decreased 26% year-over-year for FY2025 ($190.9M vs. $257.6M) and 23% for H1 2026 ($85.3M vs. $110.7M) (10-K 2025-12-31, Consolidated Statements of Operations; 10-Q 2026-06-30, MD&A Results of Operations). Total operating expenses fell 23% annually and 20% for the six-month period, driven by R&D reductions of 22% and 31% respectively, reflecting timing of manufacturing runs and development activities (10-K 2025-12-31, MD&A Research and Development Expenses; 10-Q 2026-06-30, MD&A Research and Development Expenses). G&A decreased 13% annually but rose 19% in H1 2026 due to $6.1M stock compensation and $1.6M severance from the CEO transition (10-Q 2026-06-30, MD&A General and Administrative Expenses). Impairment charges dropped from $15.7M in FY2024 to $2.4M in FY2025 and $0 in H1 2026 (10-K 2025-12-31, Consolidated Statements of Operations; 10-Q 2026-06-30, MD&A Impairment of Long-Lived Asset). Interest and other income declined modestly (4% annually, 30% for six months) due to lower yields and foreign exchange gains (10-K 2025-12-31, MD&A Interest and Other Income, Net; 10-Q 2026-06-30, MD&A Interest and Other Income, Net).

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Improving

Net cash used in operating activities improved 25% annually ($149.2M vs. $200.3M) and 51% for the first six months of 2026 ($44.9M vs. $92.0M) (10-K 2025-12-31, Consolidated Statements of Cash Flows; 10-Q 2026-06-30, Cash Flows). The improvement reflects lower net losses and favorable working capital changes, including a $23.5M release of the Servier escrow deposit in H1 2026 (10-Q 2026-06-30, Cash Flows Operating Activities). Investing cash flow swung to a $177.1M outflow in H1 2026 from a $50.0M inflow in H1 2025 due to net investment purchases ($285.4M purchases vs. $108.4M maturities), a timing difference in portfolio management (10-Q 2026-06-30, Cash Flows Investing Activities). Financing cash flow surged to $209.0M in H1 2026 from $19.1M in H1 2025, driven by the $187.9M April 2026 public offering and $20.7M ATM proceeds (10-Q 2026-06-30, Cash Flows Financing Activities). Total cash, cash equivalents and investments increased to $423.6M at June 30, 2026 from $258.3M at December 31, 2025 (10-Q 2026-06-30, Consolidated Balance Sheets; 10-K 2025-12-31, Consolidated Balance Sheets).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Improving

Total assets grew to $550.1M at June 30, 2026 from $415.9M at December 31, 2025, primarily due to the equity raise increasing short-term investments to $294.0M from $198.5M and long-term investments to $91.0M from $8.0M (10-Q 2026-06-30, Consolidated Balance Sheets; 10-K 2025-12-31, Consolidated Balance Sheets). Total liabilities declined to $113.9M from $123.4M, with the Servier escrow deposit ($23.5M) released and operating lease liabilities reduced (10-Q 2026-06-30, Consolidated Balance Sheets; 10-K 2025-12-31, Consolidated Balance Sheets). Total stockholders’ equity rose to $436.2M from $292.5M, reflecting $230.1M in net proceeds from equity issuances (public offering, ATM, ESPP) partially offset by the $85.3M six-month net loss (10-Q 2026-06-30, Consolidated Statements of Stockholders’ Equity; 10-Q 2026-06-30, Consolidated Statements of Operations). The accumulated deficit increased to $2.096B from $2.011B (10-Q 2026-06-30, Consolidated Balance Sheets; 10-K 2025-12-31, Consolidated Balance Sheets). Cash runway extended to Q1 2029 from Q1 2028 (10-Q 2026-06-30, MD&A Liquidity and Capital Resources; 10-K 2025-12-31, MD&A Liquidity and Capital Resources).

6. Data Gaps

• Quarterly revenue breakdown by program – not disclosed in any filing; only aggregate collaboration revenue from Overland is reported.
• Standalone Q3 2025 and Q4 2025 operating results – only six-month and annual aggregates are provided; Q3 2025 10-Q exists but Q3 2024 is not provided for YoY comparison.
• Detailed R&D spending by clinical program (cema-cel, ALLO-316, ALLO-329) for quarterly periods – only annual cema-cel external spend is broken out ($23.4M in FY2025, $36.4M in FY2024) (10-K 2025-12-31, MD&A Research and Development Expenses).
• Future contractual milestone payment amounts and timing – filings state amounts are contingent and cannot be estimated (10-K 2025-12-31, MD&A Contractual Obligations; 10-Q 2026-06-30, MD&A Material Cash Commitments).
• Full-year 2026 results – only six-month data available; annual 2026 10-K not yet filed.